LVLUP Health

Company Overview

LVLUP Health was founded in 2020 by Kyal Van Der Leest (nutritionist/naturopath) in Queensland, Australia. The company specializes exclusively in oral peptide formulations, typically combining multiple peptides with botanical ingredients in single products.

Products & Pricing

Product	Format	Key Ingredients	Notable
Ultimate GI Repair	Capsules	BPC-157 + KPV + GHK-Cu	Multi-peptide gut formula
Wolverine	Capsules	BPC-157 arginate + TB4-Fragment	Recovery/regeneration
Neuro Regenerate	Capsules	Dihexa + P21	Nootropic/neuroregeneration

Critical Concerns

Highly experimental compounds: Some LVLUP products contain Dihexa and P21 — compounds with extremely limited published research and essentially no human safety data. Dihexa is a synthetic angiotensin IV analogue studied in animal models for cognitive enhancement; P21 is a CNTF-derived peptide fragment. Including these in consumer products pushes beyond even the usual grey-market risk envelope.

No FDA oversight: As an Australian company, LVLUP falls under TGA jurisdiction, not the FDA. The TGA has been aggressive about peptide enforcement — Peptide Clinics Australia received a $10M penalty, and Evolution Supplements received $12M. Whether TGA has examined LVLUP specifically is not clear from available records.

Transparency Assessment

Score: 40/100 — No publicly available COAs. No named testing laboratory. No BBB listing (expected for Australian company). Limited ability for US consumers to verify quality claims.

Testing & Quality

Score: 45/100 — No evidence of third-party testing documentation accessible to consumers.

Regulatory Standing

Score: 35/100 — Scam Detector trust index of 52.5/100 (moderate-to-low). No FDA oversight. Products containing Dihexa and P21 raise additional regulatory questions. The Australian TGA’s aggressive enforcement posture against peptide companies creates ongoing compliance risk.

Customer Experience

Score: 40/100 — Trustpilot shows approximately 11 mixed reviews with shipping and customs complaints — expected for an international vendor but a practical concern for US buyers. Customs seizure is a real risk for Australian peptide imports to the US.

Red Flags

1. Dihexa and P21: Extremely experimental compounds with negligible human safety data in consumer products
2. Scam Detector 52.5/100: Below-average trust score
3. International shipping risk: Customs seizure possible for peptide imports
4. No COAs or named testing labs
5. No US regulatory oversight: FDA cannot act against Australian vendors
6. Very young company (2020): Limited operational track record

The Bottom Line

LVLUP Health’s product formulations are more adventurous than most — multi-peptide combinations with botanical additives — but the inclusion of highly experimental compounds like Dihexa and P21 crosses a risk threshold that should give consumers pause. The absence of any verifiable quality documentation, combined with a below-average trust score and international shipping complications, makes this a higher-risk vendor choice. The fact that the founder is a naturopath rather than a pharmacologist or chemist doesn’t necessarily reflect on product quality, but consumers should understand the formulation expertise behind what they’re taking.